High-risk Diabetic Patients in Medicare Part D Programs: Are They Getting the Recommended ACEI/ARB Therapy?

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al. · New England Journal of Medicine · 2001 · 7.4K citations · Full text

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke et al. · New England Journal of Medicine · 2001 · 5.9K citations · Full text

The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy

Edmund J. Lewis, Lawrence G. Hunsicker, Raymond P. Bain et al. · New England Journal of Medicine · 1993 · 5.4K citations

Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

Jeremiah Stamler, Olga Vaccaro, James D. Neaton et al. · Diabetes Care · 1993 · 4.1K citations

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy

The Lancet · 2000 · 3.2K citations

Metabolic Syndrome, Hypertension, Diabetes Management +9